Physician profile
Reena M Vaid
NPI 1104081322
$9,644.50
in general payments reported to CMS, 2019-2025
28 companies · $1,729 in 2025
The $1,729 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,200 · 2020: $788 · 2021: $677 · 2022: $1,275 · 2023: $1,368 · 2024: $1,606 · 2025: $1,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,369 · Education: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,368.56 |
| Education | $334.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,881.74 | 2019-2025 | Tremfya |
| Abbvie INC. | $1,267.54 | 2019-2025 | Rinvoq |
| Pfizer INC. | $788.07 | 2019-2025 | |
| Lilly USA, LLC | $704.98 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Amgen INC. | $487.13 | 2019-2025 | Otezla, Otezla, Enbrel |
| Ucb, INC. | $389.97 | 2019-2025 | Bimzelx |
| Incyte Corporation | $383.40 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $380.54 | 2019-2025 | |
| Galderma Laboratories, L.P. | $380.08 | 2019-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $378.03 | 2019-2025 | Cabtreo, Jublia, Siliq |
| Leo Pharma INC. | $359.10 | 2019-2025 | Anzupgo, Adbry |
| Genzyme Corporation | $294.71 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $275.85 | 2020-2024 | Absorica Ld, Winlevi, Blu-U |
| E.R. Squibb & Sons, L.L.C. | $270.63 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $259.41 | 2019-2025 | Dupixent |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $246.16 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.62 | 2023-2025 | Spevigo |
| Janssen Scientific Affairs, LLC | $122.71 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $116.56 | 2019-2020 | |
| Journey Medical Corporation | $109.64 | 2022-2024 | |
| Almirall LLC | $100.64 | 2019-2022 | |
| Botanix Sb INC | $78.91 | 2025 | Sofdra |
| Epi Health, LLC | $60.44 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $45.77 | 2024 | Zoryve |
| Sanofi-Aventis U.S. LLC | $23.01 | 2019 | |
| Dusa Pharmaceuticals, INC. | $21.89 | 2019 | |
| Encore Dermatology INC. | $21.34 | 2020 | |
| Taro Pharmaceuticals USA, INC. | $17.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Vaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.